Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

[1]  P. Wolf,et al.  Heart disease and stroke statistics--2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2006, Circulation.

[2]  R. Schrier.  Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? , 2006, Journal of the American College of Cardiology.

[3]  A. Boyle,et al.  Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. , 2005, Journal of the American College of Cardiology.

[4]  P. Sobotka,et al.  Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. , 2005, Journal of the American College of Cardiology.

[5]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[6]  K. Adams,et al.  Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). , 2005, American heart journal.

[7]  M. Haigney,et al.  Furosemide and the progression of left ventricular dysfunction in experimental heart failure. , 2004, Journal of the American College of Cardiology.

[8]  C. O'connor,et al.  Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. , 2004, American heart journal.

[9]  Eliot G. Peyster,et al.  Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). , 2003, Journal of the American College of Cardiology.

[10]  W. Abraham,et al.  Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients. , 2003, Journal of cardiac failure.

[11]  M. Gheorghiade,et al.  Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. , 2003, American heart journal.

[12]  L. Lund,et al.  Hemodilution Is Common in Patients With Advanced Heart Failure , 2003, Circulation.

[13]  S. Gottlieb,et al.  BG9719 (CVT-124), an A1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy , 2002, Circulation.

[14]  D. Ellison.  Diuretic Therapy and Resistance in Congestive Heart Failure , 2002, Cardiology.

[15]  H Ector,et al.  Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. , 2001, The New England journal of medicine.

[16]  P. Agostoni,et al.  Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. , 2001, Journal of the American College of Cardiology.

[17]  R. Mehta,et al.  Clinical Benefit and Approach of Ultrafiltration in Acute Heart Failure , 2001, Cardiology.

[18]  L. Lenert,et al.  Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. , 2001, Journal of the American College of Cardiology.

[19]  J. Schnermann,et al.  Effects of furosemide and verapamil on the NaCl dependency of macula densa-mediated renin secretion. , 1995, Hypertension.

[20]  M. Guazzi,et al.  Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. , 1994, British heart journal.

[21]  M. Guazzi,et al.  Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. , 1994, The American journal of medicine.

[22]  Bittner,et al.  Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. SOLVD Investigators. , 1993, JAMA.

[23]  William J. Rogers,et al.  Prediction of Mortality and Morbidity With a 6-Minute Walk Test in Patients With Left Ventricular Dysfunction , 1993 .

[24]  J. Cohn,et al.  Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. , 1992, American heart journal.

[25]  S. Yusuf,et al.  Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). , 1990, Circulation.

[26]  C. Cipolla,et al.  Hemofiltration as short-term treatment for refractory congestive heart failure. , 1987, The American journal of medicine.

[27]  D. Mancini,et al.  Inotropic Drugs for the Treatment of Heart Failure , 1985, Journal of clinical pharmacology.

[28]  J. Knoben,et al.  "Handbook of clinical drug data". , 1983, Canadian Medical Association journal.